APOLLOHOSP Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹7,044 Cr
verified against source
Revenue YoY
21%
reported change
EBITDA
₹1,092 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Apollo Hospitals delivered a standout Q1 FY27 with consolidated revenue of ₹7,043 crore (+21% YoY) and PAT of ₹581 crore (+34% YoY), driven by broad-based volume growth of 13% across hospitals. Healthcare services revenue hit ₹3,567 crore with established hospitals delivering 25.9% EBITDA margins, reflecting operational leverage and case mix improvement—complex quaternary care now represents 62% of inpatient net revenues. The digital pharmacy/ diagnostics vertical achieved near break-even at ₹10 crore loss, with break-even expected by Q3. New hospital losses at ₹38 crore for the quarter are tracking within the ₹150 crore annual guidance. Management confirmed hospitals segment is on track for 20% revenue growth this year, with Kodaikanal soft launch in September and revenue ramp from Q3-Q4. Expansion to 14,100 beds by FY31 remains funded by internal accruals. Key risks include regulatory scrutiny on pricing following parliamentary recommendations and insurance business losses expected to persist until Q3.
Colored figures show movement against the previous available record.
Guidance to track
- Management confirmed being on track to deliver 20% revenue growth in the hospitals segment, up from the previously guided mid-teens. Kodaikanal will contribute revenue from Q3-Q4 FY27 onward.
- The digital vertical (Apollo HealthCo) is expected to achieve break-even by end of Q3 FY27. Four insurance call centers operational with two already CM2 positive; the fourth engine (pet/retail) is being reworked.
- The cluster of new hospitals is expected to break even by Q3-Q4 of FY28, with Financial District Hyderabad breaking even next quarter and Bellis starting operations this quarter.
- Established hospitals will grow at 13-14% while new hospital contributions will add approximately 7% to overall hospital revenue over the next 24 months, sustaining the 20% blended growth trajectory.
Risks flagged
- The pet/retail insurance broker model did not work out as planned and requires rework over the next two quarters. This is extending digital business losses beyond initial expectations, though management expects Q3 break-even to hold.
- Parliamentary committee recommendations on healthcare pricing and potential price controls could impact future pricing power. Management explicitly stated that price controls may disincentivize capacity investment and innovation.
- New hospital losses will inch up by at least ₹20 crore per quarter with the opening of Kodaikanal and Bellis, before eventually declining. Maintaining the ₹150 crore annual loss guidance will be challenged.
- International patient volumes from Bangladesh are only at 60-70% of peak levels, though higher case complexity partially offsets. Full recovery trajectory remains uncertain given geopolitical factors.
Key quotes
- We've been in maybe 100 hours of dialogue with the insurance companies and all of them were appreciative of the fact that you know they could deal with this level of price increases.
- We would like to first sustain this margins. There are some cost some more cost takeouts which are possible but we would—the margins are something that we are happy with.
- If you had to notice if you didn't have insurance you're already on a positive side. So that's one business which is pulling us down. So just to be on the safe side from a guidance perspective I would say by Q3 end.
Research modules